The EU Commission Decision against Servier – a New Dimension to European Pharmaceutical Antitrust? (ESRC Centre for Competition Policy)

· 1 min read · Global Blogs

(by Sven Gallasch) On 9 July 2014 the European Commission announced its decision to impose a fine of €427.7 million on French drug maker Servier and five generic companies in relation to so-called ‘pay for delay’ settlements concerning Servier’s bestselling blood pressure drug perindopril. The case differs from the Commission’s …read more Source: Global Competition Law Blogs

Cite this post

OSCOLA

21st Century Competition, 'The EU Commission Decision against Servier – a New Dimension to European Pharmaceutical Antitrust? (ESRC Centre for Competition Policy)' (21st Century Competition, 11 July 2014) <https://www.twentyfirstcenturycompetition.com/2014/07/the-eu-commission-decision-against-servier-a-new-dimension-to-european-pharmaceutical-antitrust-esrc-centre-for-competition-policy/> accessed 7 April 2026.

Chicago

21st Century Competition. "The EU Commission Decision against Servier – a New Dimension to European Pharmaceutical Antitrust? (ESRC Centre for Competition Policy)." 21st Century Competition, 11 July 2014. https://www.twentyfirstcenturycompetition.com/2014/07/the-eu-commission-decision-against-servier-a-new-dimension-to-european-pharmaceutical-antitrust-esrc-centre-for-competition-policy/.

BibTeX

@misc{21st-century-competition2014, author = {21st Century Competition}, title = {{The EU Commission Decision against Servier – a New Dimension to European Pharmaceutical Antitrust? (ESRC Centre for Competition Policy)}}, year = {2014}, url = {https://www.twentyfirstcenturycompetition.com/2014/07/the-eu-commission-decision-against-servier-a-new-dimension-to-european-pharmaceutical-antitrust-esrc-centre-for-competition-policy/}, note = {21st Century Competition} }
Download .bib file

Related Posts